Published on
November 19, 2025
In the media
Our lead oncology asset is nominated for Best Biomedical Product at Prix Galien Bridges Awards, recognizing its potential in advancing cancer therapeutics.
About Greywolf Therapeutics
Greywolf Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology to guide the immune system. Our approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. We are progressing first-in-class antigen modulators to treat people living with cancers, autoimmune disorders, and infectious diseases.
Greywolf is headquartered in Oxford, UK.
More information: Website | LinkedIn
Media enquiries
Patrick White, Head of Communications
